Abstract 4535
Background
UC is platinum-responsive and hypothesized to be sensitive to targeted DNA-damaging agents such as PARP inhibitors (PARPi). Cisplatin (cis)-ineligible pts with metastatic/unresectable primary UC have limited effective treatment options. Immune checkpoint blockade may increase the proportion of pts that respond to PARPi. Durvalumab is a selective, high-affinity, engineered, human IgG1 monoclonal Ab that blocks PD-L1 binding to PD-1 and CD80. In UC, the combination of olaparib (a PARPi) + durvalumab may broaden the therapeutic effect of monotherapy given their different mechanisms of action, with potentially enhanced benefit for pts with metastatic/unresectable UC and DNA repair deficiencies (mutations in homologous recombination repair genes [HRRm]).
Trial design
BAYOU is a double-blind, randomized, placebo-controlled, multicenter phase 2 study designed to assess the efficacy and safety of durvalumab + olaparib vs durvalumab + placebo in cis-ineligible pts with stage IV UC. Adult pts (≥18 years) who are cis-ineligible with histologically/cytologically confirmed unresectable stage IV UC, WHO performance status 0-2, and with known HRRm status will be enrolled. Pts with active/prior autoimmune disorders, brain metastases, prior PARPi/immune therapy, current/prior immunosuppressive agents, non-UC invasive malignancies, and concomitant use of strong CYP3A inhibitors/inducers are excluded. All pts will be randomized (1:1) to durvalumab (1500 mg intravenous, every 4 weeks) + placebo or durvalumab + olaparib (tablet) until disease progression. Olaparib dose will be 300 mg twice daily in pts with CrCl >50 mL/min and 200 mg twice daily in pts with CrCl ≥31 to ≤ 50 mL/min. The primary endpoint is progression-free survival in HRRm patients (investigator assessed, RECIST v1.1). Secondary endpoints are overall survival (OS), duration of response, objective response rate, proportion of pts alive and progression free at 6 months, and OS at 18 months. Safety, pharmacokinetics, and immunogenicity will also be assessed. The trial is currently enrolling pts.
Clinical trial identification
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Editorial Acknowledgement
Editorial assistance, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Ingrid Monteiro of Cactus Communications (Mumbai, India).
Disclosure
J.E. Rosenberg: Stockholder: Ilumina; Advisory board: Merck, BMS, AstraZeneca, EMD-Serono, Roche/Genentech, Inovio; Corporate-sponsored research: Roche/Genentech, Seattle Genetics, Astellas, Novartis. D.F. Bajorin: Advisory board or board of directors: Merck, Genentech, Bristol-Myers Squibb, Urogen, Novartis; Corporate-sponsored research: Merck, Novartis. A. Smith, C. D’Cruz, M. Lanasa: Employment: AstraZeneca; Stockholder: AstraZeneca.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract